Iridex (IRIX) Asset Writedowns and Impairment (2011 - 2025)

Iridex's (IRIX) quarterly Asset Writedowns and Impairment came in at $800000.0 in Q3 2025, up 892.08% quarter-over-quarter from -$101000.0 in Q1 2022.

Iridex (IRIX) Asset Writedowns and Impairment (2011 - 2025) Analysis & Trends

Iridex's Asset Writedowns and Impairment history runs 11 years deep, the most recent figure standing at $800000.0 for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $800000.0 in Q3 2025; TTM through Jan 2026 was $800000.0, a 1350.0% increase from a year earlier, with the FY2026 full-year figure at $823000.0, changed N/A from the prior year.
  • Asset Writedowns and Impairment grew to $800000.0 in Q3 2025 per IRIX's latest filing, from -$101000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $800000.0 in Q3 2025 and bottomed at -$101000.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn
8 Smith & Nephew 26.99 Bn 26.41 Bn -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn
10 Iridex 15.41 Mn 10.81 Mn 4.74 Mn

Historic Data

Download Data
DateValue
Sep 27, 2025 800,000.00
Sep 27, 2025 800,000.00
Jan 1, 2022 -101,000.00
Jan 1, 2022 -101,000.00
Sep 26, 2020 37,000.00
Sep 26, 2020 37,000.00
Jun 27, 2020 59,000.00
Jun 27, 2020 59,000.00
Mar 28, 2020 42,000.00
Mar 28, 2020 42,000.00
Mar 30, 2019 25,000.00
Mar 30, 2019 25,000.00
Dec 30, 2017 39,000.00
Dec 30, 2017 39,000.00
Sep 30, 2017 -14,000.00
Sep 30, 2017 -14,000.00
Dec 31, 2016 120,000.00
Dec 31, 2016 120,000.00
Oct 1, 2016 25,000.00
Oct 1, 2016 25,000.00